Uudised

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

september 3, 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

Loe edasi "

Chronicle of a Relentless Quest: The Making of a Foundation

1. august 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

Loe edasi "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

juuli 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

Loe edasi "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

juuli 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

Loe edasi "

Wave Life Sciences annab teada positiivsetest tulemustest faasi 1b/2a uuringust SELECT-HD, mis näitab esmakordselt kliiniliselt, et Huntingtoni tõve all-selektiivne mutant Huntingtin vähendab Huntingtoni tõbe

juuni 25, 2024

Täna teatas Wave Life Sciences positiivsetest tulemustest SELECT-HD, meie platseebokontrolliga faasi 1b/2a uuringust, milles hinnatakse uuritavat ravi WVE-003. Need tulemused näitavad, et WVE-003 vähendab selektiivselt toksilist, mutantset huntingtiini (mHTT) valku ja säilitab terve, metsikut tüüpi huntingtiini (wtHTT) valgu Huntingtoni tõvega isikute puhul. Uuringu tulemusedAnalüüsis võrreldi

Loe edasi "

Lähis-Ida ja Põhja-Aafrika ajakohastatud teave

juuni 3, 2024

IHA president Svein Olaf Olsen oli eelmisel kuul Abu Dhabis toimunud MENA haruldaste haiguste kongressi peaesineja Huntingtoni tõve teemal. Ta rääkis tungivast vajadusest luua piirkonnas neurodegeneratiivsete haiguste tippkeskus ja edendada kliinilisi uuringuid. See sobib ideaalselt kokku piirkonna kavatsusega

Loe edasi "

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

september 3, 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

Loe edasi "

Chronicle of a Relentless Quest: The Making of a Foundation

1. august 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

Loe edasi "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

juuli 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

Loe edasi "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

juuli 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

Loe edasi "

Wave Life Sciences annab teada positiivsetest tulemustest faasi 1b/2a uuringust SELECT-HD, mis näitab esmakordselt kliiniliselt, et Huntingtoni tõve all-selektiivne mutant Huntingtin vähendab Huntingtoni tõbe

juuni 25, 2024

Täna teatas Wave Life Sciences positiivsetest tulemustest SELECT-HD, meie platseebokontrolliga faasi 1b/2a uuringust, milles hinnatakse uuritavat ravi WVE-003. Need tulemused näitavad, et WVE-003 vähendab selektiivselt toksilist, mutantset huntingtiini (mHTT) valku ja säilitab terve, metsikut tüüpi huntingtiini (wtHTT) valgu Huntingtoni tõvega isikute puhul. Uuringu tulemusedAnalüüsis võrreldi

Loe edasi "

Lähis-Ida ja Põhja-Aafrika ajakohastatud teave

juuni 3, 2024

IHA president Svein Olaf Olsen oli eelmisel kuul Abu Dhabis toimunud MENA haruldaste haiguste kongressi peaesineja Huntingtoni tõve teemal. Ta rääkis tungivast vajadusest luua piirkonnas neurodegeneratiivsete haiguste tippkeskus ja edendada kliinilisi uuringuid. See sobib ideaalselt kokku piirkonna kavatsusega

Loe edasi "
etEstonian
en_USEnglish arArabic bg_BGBulgarian zh_CNChinese cs_CZCzech da_DKDanish nl_NLDutch fiFinnish fr_FRFrench de_DEGerman elGreek hu_HUHungarian id_IDIndonesian it_ITItalian jaJapanese lvLatvian lt_LTLithuanian pl_PLPolish pt_PTPortuguese ro_RORomanian ru_RURussian sk_SKSlovak sl_SISlovenian es_ESSpanish sv_SESwedish tr_TRTurkish ukUkrainian etEstonian
Skip to content